A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013-present)

REFERENCES

• Misztak P, Pańczyszyn-Trzewik P, Sowa-Kućma M. Histone deacetylases (HDACs) as therapeutic target for depressive disorders. Pharmacol Rep. 2018;70(2):398–408. doi: 10.1016/j.pharep.2017.08.001
   PubMed Web of Science ®Google Scholar
• Chen QW, Zhu XY, Li YY, et al. Epigenetic regulation and cancer (review). Oncol Rep. 2014;31(2):523–532. doi: 10.3892/or.2013.2913
   PubMed Web of Science ®Google Scholar
• Biswas S, Rao CM Epigenetics in cancer: Fundamentals and Beyond. Pharmacol Ther. 2017;173:118–134. doi:10.1016/j.pharmthera.2017.02.011
   PubMed Web of Science ®Google Scholar
• Adhikari N, Jha T, Ghosh B. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy. J. Med. Chem. 2021;64(13):8827–8869. doi:10.1021/acs.jmedchem.0c01676
   PubMed Web of Science ®Google Scholar
• Banerjee S, Adhikari N, Amin SA, et al. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. Eur. J. Med. Chem. 2019;164:214–240. doi:10.1016/j.ejmech.2018.12.039
   PubMed Web of Science ®Google Scholar
• Müller MM, Muir TW. Histones: at the crossroads of peptide and protein chemistry. Chem. Rev. 2015;115(6):2296–2349. doi:10.1021/cr5003529
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Oehme I, Witt O, et al. HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol. Sci. 2015;36(7):481–492. doi:10.1016/j.tips.2015.04.013
   PubMed Web of Science ®Google Scholar
• Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur. J. Med. Chem. 2016;121:451–483. doi:10.1016/j.ejmech.2016.05.047
   PubMed Web of Science ®Google Scholar
• Rajaraman S, Balakrishnan R, Deshmukh D, et al. HDAC8 as an emerging target in drug discovery with special emphasis on medicinal chemistry. Future Med Chem. 2023;15(10):885–908. doi: 10.4155/fmc-2023-0054
   PubMed Web of Science ®Google Scholar
• Amin SA, Adhikari N, Jha T Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?. Pharmacol Res. 2017;122:8–19. doi:10.1016/j.phrs.2017.05.002
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Melesina J, Kolbinger FR, et al. Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. Future Med. Chem. 2016;8(13):1609–1634. doi:10.4155/fmc-2016-0117
   PubMed Web of Science ®Google Scholar
• Nian H, Bisson WH, Dashwood WM, et al. Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis. 2009;30(8):1416–1423. doi: 10.1093/carcin/bgp147
   PubMed Web of Science ®Google Scholar
• Kim JY, Cho H, Jung Yoo J, et al. HDAC8 Deacetylates HIF-1α and enhances its protein stability to promote tumor growth and migration in melanoma. Cancers (Basel). 2023; 15(4):1123. doi: 10.3390/cancers15041123.
   PubMed Web of Science ®Google Scholar
• Olson DE, deshi ND, Wolfson NA, et al. An unbiased approach to identify endogenous substrates of “histone” deacetylase 8. ACS Chem Biol. 2014; 9(10):2210–2216. doi: 10.1021/cb500492r.
   PubMed Web of Science ®Google Scholar
• Tang X, Li L, Su F, et al. HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. Nucleic Acids Res. 2020; 48(6): 2912–2923. doi: 10.1093/nar/gkaa039.
   PubMed Web of Science ®Google Scholar
• Adhikari N, Amin SA, Jha T. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review. Pharm Pat Anal. 2018;7(6):259–276. doi: 10.4155/ppa-2018-0019
   PubMedGoogle Scholar
• Marek M, Shaik TB, Heimburg T, et al. Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants. J Med Chem. 2018;61(22):10000–10016. doi: 10.1021/acs.jmedchem.8b01087
   PubMed Web of Science ®Google Scholar
• https://www.rcsb.org/
   Google Scholar
• Amin SA, Adhikari N, Jha T. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery. Future Med Chem. 2017; 9(18):2211–2237. doi: 10.4155/fmc-2017-0130.
   PubMed Web of Science ®Google Scholar
• Stenzel K, Hamacher A, Hansen FK, et. al. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines. J Med Chem. 2017; 60(13):5334–5348. doi: 10.1021/acs.jmedchem.6b01538.
   PubMed Web of Science ®Google Scholar
• Mwakwari SC, Patil V, Guerrant W, et al. Macrocyclic histone deacetylase inhibitors. Curr Top Med Chem. 2010;10(14):1423–1440. doi: 10.2174/156802610792232079
   PubMed Web of Science ®Google Scholar
• Fontana A, Cursaro I, Carullo G, et al. A therapeutic perspective of HDAC8 in different diseases: an overview of selective inhibitors. Int J Mol Sci. 2022;23(17):10014. doi: 10.3390/ijms231710014
   PubMed Web of Science ®Google Scholar
• Kim JY, Cho H, Yoo J, et al. Pathological Role of HDAC8: Cancer and Beyond. Cells. 2022; 11(19):3161. doi: 10.3390/cells11193161.
   PubMed Web of Science ®Google Scholar
• Chen J, Cao L, Ma J, et al. HDAC8 promotes liver metastasis of colorectal cancer via inhibitionof irf1 and upregulation of SUCNR1. Oxid. Med. Cell Longev. 2022, 2815187 (2022).
   PubMed Web of Science ®Google Scholar
• Menbari MN, Rahimi K, Ahmadi A, et al. Association of HDAC8 expression with pathological findings in triple negative and non-triple negative breast cancer: implications for diagnosis. Iran Biomed. J. 24(5), 288–294 (2020).
   PubMedGoogle Scholar
• Li Y, Liang R, Sun M, et al. AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation. Cancer Lett. 2020;478:82–92. doi: 10.1016/j.canlet.2020.03.007
   PubMed Web of Science ®Google Scholar
• Kim JY, Han SY, Yoo J, et al. HDAC8-selective inhibition by PCI-34051 enhances the anticancer effects of ACY-241 in ovarian cancer cells. Int. J. Mol. Sci. 23(15), 8645 (2022).
   PubMed Web of Science ®Google Scholar
• Vanaja GR, Ramulu HG, Kalle AM. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6. Cell Commun. Signal. 16(1), 20 (2018).
   PubMedGoogle Scholar
• Mahajan M, Suryavanshi S, Bhowmick S, et al. Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity. Biophys. Chem. 273, 106588 (2021).
   PubMed Web of Science ®Google Scholar
• Song S, Wang Y, Xu P, et al. The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma. Int. J. Oncol. 47(5), 1819–1828 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang M, Ying JB, Wang SS, et al. Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of cap group. J. Cell Biochem. 121(5–6), 3162–3172 (2020).
   PubMed Web of Science ®Google Scholar
• Kang Y, Nian H, Rajendran P, et al. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis. 2014;5(10):e1476. doi: 10.1038/cddis.2014.422
   PubMedGoogle Scholar
• Oehme I, Deubzer HE, Lodrini M, et al. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs. 2009;18(11):1605–1617. doi:10.1517/14728220903241658
   PubMed Web of Science ®Google Scholar
• Lehmann M, Hoffmann MJ, Koch A, et al. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. J Exp Clin Cancer Res. 2014;33(1):59. doi:10.1186/s13046-014-0059-8
   PubMedGoogle Scholar
• Ahn MY, Yoon JH. Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. Oncol Rep. 2017;37(1):540–546. doi:10.3892/or.2016.5280
   PubMed Web of Science ®Google Scholar
• Santos-Barriopedro I, Li Y, Bahl S, et al. HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1. Genes Cancer. 2019;10(5–6):119–133. doi:10.18632/genesandcancer.197
   PubMedGoogle Scholar
• Lopez G, Bill KL, Bid HK, et al. HDAC8, a potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST). PLoS One. 10(7), e0133302 (2015).
   PubMed Web of Science ®Google Scholar
• Tian Y, Wong VW, Wong GL, et al. Histone deacetylase HDAC8 promotes insulin resistance and β-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res. 75(22), 4803–4816 (2015).
   PubMed Web of Science ®Google Scholar
• Watters JM, Wright G, Smith MA, Shah B, Wright KL. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. Biochem. Biophys. Res. Commun. 534, 773–779 (2021).
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Ramos J, Luo W, et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22(5):1026–1034. doi:10.1038/leu.2008.9
   PubMed Web of Science ®Google Scholar
• Spreafico M, Gruszka AM, Valli D, et al. HDAC8: a promising therapeutic target for acute myeloid leukemia. Front. Cell Dev. Biol. 8, 844 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang P, Brinton LT, Williams K, et al. Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition. Clin. Cancer Res. 27(8), 2352–2366 (2021).
   PubMed Web of Science ®Google Scholar
• Qi J, Singh S, Hua WK, et al. HDAC8 inhibition specifically targets Inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation. Cell Stem Cell. 2015;17(5):597–610. doi: 10.1016/j.stem.2015.08.004
   PubMed Web of Science ®Google Scholar
• Yoon JI, Cho H, Jeon R, et al. Therapeutic efficacy of novel HDAC inhibitors SPA3052 and SPA3074 against intestinal inflammation in a murine model of colitis. Pharmaceuticals (Basel). 2022;15(12):1515. doi:10.3390/ph15121515
   PubMedGoogle Scholar
• Zhou X, Chen H, Shi Y, et al. Histone deacetylase 8 inhibition prevents the progression of peritoneal fibrosis by counteracting the epithelial-mesenchymal transition and blockade of M2 macrophage polarization. Front. Immunol. 14, 1137332 (2023).
   PubMed Web of Science ®Google Scholar
• Saito S, Zhuang Y, Suzuki T, et al. HDAC8 inhibition ameliorates pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 316(1), L175–L186 (2019).
   PubMed Web of Science ®Google Scholar
• Spreafico M, Cafora M, Bragato C, et al. Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy. Pharmacol Res. 2021;170:105750. doi: 10.1016/j.phrs.2021.105750
   PubMed Web of Science ®Google Scholar
• Xiao T, Fu Y, Zhu W, et al. HDAC8, a potential therapeutic target, Regulates proliferation and differentiation of bone marrow stromal cells in fibrous dysplasia. Stem. Cells Transl. Med. 8(2), 148–161 (2019).
   PubMed Web of Science ®Google Scholar
• Deardorff MA, Porter NJ, Christianson DW. Structural aspects of HDAC8 mechanism and dysfunction in cornelia de lange syndrome spectrum disorders. Protein Sci. 2016;25(11):1965–1976. doi:10.1002/pro.3030
   PubMed Web of Science ®Google Scholar
• Mio C, Passon N, Fogolari F, et al. A novel de novo HDAC8 missense mutation causing Cornelia de Lange syndrome. Mol. Genet. Genomic. Med. 9(9), e1612 (2021).
   PubMed Web of Science ®Google Scholar
• Lee CH, Choi Y, Cho H, et al. Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis. Biochem. Pharmacol. 183, 114312 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zou J, Tolbert E, et al. Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis. Faseb J. 2020;34(6):7295–7310. doi:10.1096/fj.201903254R
   PubMed Web of Science ®Google Scholar
• Marek M, Kannan S, Hauser AT, et al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke schistosoma mansoni. PloS Pathog. 2013;9(9):e1003645. doi: 10.1371/journal.ppat.1003645
   PubMed Web of Science ®Google Scholar
• Noce B, Di Bello E, Zwergel C, et al. Chemically diverse S. mansoni HDAC8 inhibitors reduce viability in worm larval and adult stages. ChemMedchem. 2023;18(3):e202200510. doi: 10.1002/cmdc.202200510
   PubMed Web of Science ®Google Scholar
• Xia B, Lu J, Wang R, Yang Z, Zhou X, Huang P. miR-21-3p regulates influenza a virus replication by targeting histone deacetylase-8. Front. Cell Infect. Microbiol. 8, 175 (2018).
   PubMed Web of Science ®Google Scholar
• Chen Y, Pan C, Lu Y, et al. HDAC8 drives spindle organization during meiotic maturation of porcine oocytes. Cell Prolif. 2021;54(10):e13119. doi:10.1111/cpr.13119
   PubMed Web of Science ®Google Scholar
• Ho TCS, Chan AHY, Ganesan A. Thirty years of HDAC inhibitors: 2020 insight and Hindsight. J Med Chem. 2020;63(21):12460–12484. doi: 10.1021/acs.jmedchem.0c00830
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. [accessed 2024 Mar 31]. Available from: https://clinicaltrials.gov
   Google Scholar
• The J. David Gladstone Institutes, Ithaca College. Inhibitors for hdac8. 2008: WO2008101186A1
   Google Scholar
• Shandong University. Tyrosine derivative histone deacetylases inhibitor and application thereof. 2010; CN101723896
   Google Scholar
• S*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications. 2005; WO2005040161A1
   Google Scholar
• Sookmyung Women’s University Industry-Academic Cooperation Foundation. Novel binary histone deacetylase inhibitor and pharmaceutical composition containing same. 2022; WO2023177249A1.
   Google Scholar
• Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors. 2017; WO2017040963A1
   Google Scholar
• Shandong University, Histone deacetylase 8 selective depressant and its preparation method and application. 2018; CN108299255A.
   Google Scholar
• Institute of Chemical Industry of Forest Products of CAF. Synthesis method of methylene ether urushiol hydroxamic acid derivative with HDAC (Histone-like oxidase) inhibitory activity. 2019; CN110256398B.
   Google Scholar
• Institute of Chemical Industry of Forest Products of CAF. Synthesis method of novel urushiol-based hydroxamic acid derivatives having HDAC (Histone deacetylase) inhibition and antitumor activity. 2020; CN111440138A
   Google Scholar
• Institute of Chemical Industry of Forest Products of CAF. Urushiol-based hydroxamic acid HDAC inhibitor with targeted antitumor activity and preparation method and application thereof. 2023; CN116375698B.
   Google Scholar
• Pharmacyclics LLC. Indole derivatives as inhibitors of histone deacetylase. 2016; US9371281.
   Google Scholar
• Pharmacyclics LLC. Uses of selective inhibitors of hdac8 and treatment of inflammatory conditions. 2015; US20150038542A1.
   Google Scholar
• Stomatological Hospital of Nanjing Medical University. Application of the HDAC8 inhibitor in the drug of preparation treatment fibrous dysplasia. 2019; CN110420208A.
   Google Scholar
• Pharmacyclics LLC. Selective inhibitors of histone deacetylase. 2016; EP2265590B1.
   Google Scholar
• Pharmacyclics, Inc. Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8. 2013, WO2013101600A1.
   Google Scholar
• Nagoya City University. Hydroxamic acid derivative and HDAC8 inhibitor using the same. 2015; JP5725475B2.
   Google Scholar
• Kyoto Prefectural Public Univ Corp, Nagoya City University, Tak Circulator Co Ltd. Hydroxamic acid derivatives and hdac8 inhibitors. 2016; JP2016017040A.
   Google Scholar
• Hainan Research Institute Of Zhejiang University. HDAC8 inhibitor and preparation method and application thereof. 2023; CN117430565.
   Google Scholar
• Forma Therapeutics Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors. 2017; US9745253B2.
   Google Scholar
• Boston University, Dana Farber Cancer Institute Inc. Selective histone deacetylase 8 inhibitors. 2018; US10087149B2.
   Google Scholar
• Valo Health Inc. [6,6] fused bicyclic HDAC8 inhibitors. 2022; US11414392B2.
   Google Scholar
• Academia Sinica, Taipei Medical University TMU, City of Hope. HDAC8 inhibitors for treating cancer. 2019; US10308596B2.
   Google Scholar
• Incyte Corp. Heterocyclic compounds and uses thereof. 2020; US10723705B2.
   Google Scholar
• Broad Institute Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors. 2020; US10793538B2.
   Google Scholar
• Council of Scientific and Industrial Research CSIR. Indole (sulfomyl) n-hydroxy benzamide derivatives as selective HDAC inhibitors. 2021; US11072583B2.
   Google Scholar
• Wayne State University. Structural requirements of histone deacetylase inhibitors: C4-modified saha analogs display dual HDAC6/HDAC8 selectivity. 2018; US20180057448A1.
   Google Scholar
• Shenzhen University. Selective histone deacetylase 8 degrader, preparation method and application thereof in anti-tumor activity. 2023; WO2023151113A1.
   Google Scholar
• Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation. 3,4-dihydroquinoxaline-2-carboximide derivative compound and pharmaceutical composition comprising same for preventing or treating cancer disease. 2023; WO2023191379A1.
   Google Scholar
• Kan Saila Co Ltd. It can be used as the bicycle hydroxamic acid compound of the inhibitor of mammal histone deacetylase activity. 2018; CN108602812A.
   Google Scholar
• Sookmyung Women’s University Industry-Academic Cooperation Foundation. Novel Compounds, preparation method thereof, and pharmaceutical composition for use in preventing or treating Neuroblastoma containing the same as an active ingredient. 2019; KR20190087799A.
   Google Scholar
• Cava Healthcare Inc. Compounds for increasing mhc-i expression and modulating histone deacetylase activity. 2022; US20220105051A1.
   Google Scholar
• Klotho Therapeutics, Inc. Novel heterocyclic compounds and related methods of manufacture and use in hdac inhibition. 2022; WO2022178544A1.
   Google Scholar
• Kyushu University NUC. Histone deacetylation enzyme inhibitor, food (health supplement) or medicine, bittering agent, and drug using this inhibitor, and production methods thereof. 2018; JP2018104396A.
   Google Scholar
• Universidade de de Aveiro. Nitro-containing compounds, compositions and uses thereof. 2024; EP4306106A1.
   Google Scholar
• Hochschule Darmstadt. Selective hdac8 inhibitors and their uses. 2018; US20180311257A1.
   Google Scholar
• University Of Connecticut. Substituted tropolone derivatives and methods of use. 2013; WO2013192554A1.
   Google Scholar
• Banerjee S, Baidya SK, Adhikari N, Jha T. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches. SAR QSAR Environ. Res. 2022;33(12):987–1011. doi:10.1080/1062936X.2022.2155241
   PubMedGoogle Scholar
• Banerjee S, Amin SA, Adhikari N, Jha T. Essential elements regulating HDAC8 inhibition: a classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors. J. Biomol. Struct. Dyn. 2020;38(18):5513–5525. doi:10.1080/07391102.2019.1704881
   PubMed Web of Science ®Google Scholar
• Banerjee S, Adhikari N, Amin SA, et al. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study. J Biomol Struct Dyn. 2020;38(5):1551–1564. doi: 10.1080/07391102.2019.1617782
   PubMed Web of Science ®Google Scholar
• Wolff B, Jänsch N, Sugiarto WO, et al. Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors. Eur J Med Chem. 2019 Dec 15;184:111756. doi: 10.1016/j.ejmech.2019.111756.
   PubMed Web of Science ®Google Scholar
• Muth M, Jänsch N, Kopranovic A, et al. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine. Biochim Biophys Acta Gen Subj. 2019;1863(3):577–585. doi: 10.1016/j.bbagen.2019.01.001.
   PubMed Web of Science ®Google Scholar